KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other financing activities (2020 - 2022)

Historic Other financing activities for Halozyme Therapeutics (HALO) over the last 5 years, with Q4 2022 value amounting to $639000.0.

  • Halozyme Therapeutics' Other financing activities changed N/A to $639000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was $1.1 million, marking a year-over-year decrease of 8450.17%. This contributed to the annual value of $7.1 million for FY2022, which is 157547.17% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Other financing activities stood at $639000.0 for Q4 2022.
  • Halozyme Therapeutics' 5-year Other financing activities high stood at $6.0 million for Q2 2022, and its period low was -$68000.0 during Q2 2020.
  • In the last 3 years, Halozyme Therapeutics' Other financing activities had a median value of $329000.0 in 2021 and averaged $1.1 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Other financing activities skyrocketed by 23970.59% in 2021 and then soared by 621894.74% in 2022.
  • Quarter analysis of 3 years shows Halozyme Therapeutics' Other financing activities stood at -$68000.0 in 2020, then soared by 239.71% to $95000.0 in 2021, then soared by 572.63% to $639000.0 in 2022.
  • Its last three reported values are $639000.0 in Q4 2022, $462000.0 for Q3 2022, and $6.0 million during Q2 2022.